Etude de phase II évaluant l’association de cetuximab à une radiothérapie et chimiothérapie concomitante par cisplatine et pemetrexed dans le traitement des cancers bronchiques non à petites cellules non-épidermoïdes de stade III, inopérables

Phase 1

• Conditions: Stage III Non-small cell lung cancer; MedDRA version: 12.0Level: LLTClassification code 10025052Term: Lung cancer non-small cell stage III

• Registration Number: EUCTR2009-012412-41-FR
• Lead Sponsor: IFCT

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2009-11-13
• Last Update Posted: 4 July 2016

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

-[1] patient with NSCLC with non-squamous predominant histology
-[2] patient with stage III NSCLC (classification TNM 2009) non-resectable, non-irradiable,
-[3] One mesurable lesion(RECIST 1.1),
-[12] age = 18 and < 70 ,
-[13] Performance status OMS 0 or 1,

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Not provided

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Main Objective: Efficacy (Disease control rate after 16 weeks);Secondary Objective: Tolerance<br>Progression-free Survival<br>Overall Suvival;Primary end point(s): Disease Control Rate (at 16th week)